Based on these observations, despite incorporation into the propensity score-matched analysis, the TTF1 expression level did not significantly affect the effectiveness of pembrolizumab monotherapy or chemoimmunotherapy in patients with PD-L1 high-expressing non-Sq NSCLC. Here, TTF1 is linked to non-small cell lung carcinoma.